Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms

Published:2018-02-22 Issue:3 Volume:9 Page:
ISSN:2041-4889
Container-title:Cell Death & Disease
language:en
Short-container-title:Cell Death Dis

Author:

Machado-Neto João Agostinho,Fenerich Bruna Alves,Scopim-Ribeiro Renata,Eide Christopher A.,Coelho-Silva Juan Luiz,Dechandt Carlos Roberto Porto,Fernandes Jaqueline Cristina,Rodrigues Alves Ana Paula Nunes,Scheucher Priscila Santos,Simões Belinda Pinto,Alberici Luciane Carla,de Figueiredo Pontes Lorena Lôbo,Tognon Cristina E.,Druker Brian J.,Rego Eduardo Magalhães,Traina Fabiola

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/s41419-017-0256-4.pdf

Reference55 articles.

1. Thoennissen, N. H. et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 115, 2882–2890 (2010).

2. Pardanani, A. et al. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 25, 218–225 (2011).

3. Harrison, C. et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366, 787–798 (2012).

4. Verstovsek, S. et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366, 799–807 (2012).

5. Vannucchi, A. M. et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372, 426–435 (2015).

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolism and bioenergetics in the pathophysiology of organ fibrosis;Free Radical Biology and Medicine;2024-09

2. The survivin/XIAP suppressant YM155 impairs clonal growth and induces apoptosis in JAK2V617F cells;Hematology, Transfusion and Cell Therapy;2024-09

3. Metformin for MPN: teaching an old drug new tricks;Blood Advances;2024-08-27

4. Metformin use and risk of myeloproliferative neoplasms: a Danish population–based case-control study;Blood Advances;2024-08-27

5. Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients;Cancers;2024-06-28